Shares of Xencor, Inc. (NASDAQ:XNCR) have been assigned an average recommendation of “Hold” from the nine analysts that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $28.00.

XNCR has been the subject of several recent research reports. Canaccord Genuity restated a “buy” rating and set a $36.00 target price on shares of Xencor in a report on Tuesday, August 8th. ValuEngine upgraded shares of Xencor from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Zacks Investment Research cut shares of Xencor from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Finally, BidaskClub cut shares of Xencor from a “hold” rating to a “sell” rating in a report on Monday, August 14th.

TRADEMARK VIOLATION NOTICE: “Xencor, Inc. (XNCR) Receives Consensus Rating of “Hold” from Analysts” was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/11/02/xencor-inc-xncr-receives-consensus-rating-of-hold-from-analysts.html.

In other news, major shareholder John S. Stafford III purchased 50,000 shares of the business’s stock in a transaction on Thursday, November 2nd. The stock was purchased at an average price of $19.58 per share, for a total transaction of $979,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder John S. Stafford III purchased 41,016 shares of the business’s stock in a transaction on Tuesday, August 22nd. The stock was purchased at an average price of $19.69 per share, with a total value of $807,605.04. The disclosure for this purchase can be found here. Insiders have purchased 453,904 shares of company stock valued at $9,102,120 in the last 90 days. 4.03% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in XNCR. FMR LLC lifted its stake in Xencor by 77.7% in the second quarter. FMR LLC now owns 6,690,258 shares of the biopharmaceutical company’s stock valued at $141,232,000 after acquiring an additional 2,924,510 shares during the last quarter. State Street Corp lifted its stake in Xencor by 17.5% in the first quarter. State Street Corp now owns 992,981 shares of the biopharmaceutical company’s stock valued at $23,751,000 after acquiring an additional 148,136 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Xencor by 57.4% in the first quarter. Dimensional Fund Advisors LP now owns 286,894 shares of the biopharmaceutical company’s stock valued at $6,863,000 after acquiring an additional 104,638 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Xencor by 48.1% in the second quarter. JPMorgan Chase & Co. now owns 289,500 shares of the biopharmaceutical company’s stock valued at $6,112,000 after acquiring an additional 93,975 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Xencor by 5.6% in the second quarter. Vanguard Group Inc. now owns 1,701,209 shares of the biopharmaceutical company’s stock valued at $35,913,000 after acquiring an additional 90,094 shares during the last quarter. Hedge funds and other institutional investors own 76.81% of the company’s stock.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.10. The company had revenue of $13.34 million during the quarter, compared to analysts’ expectations of $8.15 million. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.